← Browse by Condition
Medical Condition

myasthenia gravis

Total Trials
9
Recruiting Now
9
Trial Phases
Phase 1, Phase 2, Phase 3, Phase 2, Phase 3
NCT06006832
Recruiting

A Prospective Cohort Study of Myasthenia Gravis in China

Enrollment
202 pts
Location
China
Sponsor
Peking Union Medical College H...
View Trial →
NCT06106672 Phase 1, Phase 2
Recruiting

Evaluate the Safety, Tolerability, Pharmacodynamics and Efficacy of CNP-106 in Subjects With Myasthenia Gravis

Enrollment
54 pts
Location
United States
Sponsor
COUR Pharmaceutical Developmen...
View Trial →
NCT04951622 Phase 3
Recruiting

A Study of Nipocalimab Administered to Adults With Generalized Myasthenia Gravis

Enrollment
199 pts
Location
United States, Austr...
Sponsor
Janssen Research & Development...
View Trial →
NCT05337891
Recruiting

Sensitivity of Repetitive Nerve Stimulation Performed in the Evening vs in the Morning in Myasthenia Gravis

Enrollment
40 pts
Location
Poland
Sponsor
Jagiellonian University
View Trial →
NCT06193889 Phase 2, Phase 3
Recruiting

KYSA-6: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, in Patients With Generalized Myasthenia Gravis

Enrollment
66 pts
Location
United States, Brazi...
Sponsor
Kyverna Therapeutics
View Trial →
NCT07294170
Recruiting

ADAPT Forward - Master Protocol of a Platform Study to Evaluate the Safety and Efficacy of Multiple Regimens in Participants With Myasthenia Gravis

Enrollment
70 pts
Location
United States
Sponsor
argenx
View Trial →
NCT06414954 Phase 2
Recruiting

Safety and Efficacy of 3 Dose Levels of NMD670 in Adult Patients With Myasthenia Gravis

Enrollment
84 pts
Location
United States, Belgi...
Sponsor
NMD Pharma A/S
View Trial →
NCT01793168
Recruiting

Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford

Enrollment
20,000 pts
Location
United States, Austr...
Sponsor
Sanford Health
View Trial →
NCT07022197 Phase 1, Phase 2
Recruiting

Safety and Efficacy of BAFF-R CART for Refractory Neuroimmune Diseases

Enrollment
27 pts
Location
China
Sponsor
Tianjin Medical University Gen...
View Trial →